M Goorden1, E van der Schee2, V M Hendriks3, L Hakkaart-van Roijen4. 1. Institute for Medical Technology Assessment & Institute of Health Policy & Management, P.O. Box 1738, 3000 DR, Erasmus University Rotterdam, The Netherlands. Electronic address: Goorden@bmg.eur.nl. 2. Parnassia Addiction Research Centre (PARC), Brijder Addiction Treatment, Parnassia Group, P.O. Box 53002, 2505 AA The Hague, The Netherlands. 3. Parnassia Addiction Research Centre (PARC), Brijder Addiction Treatment, Parnassia Group, P.O. Box 53002, 2505 AA The Hague, The Netherlands; Curium, Leiden University Medical Center, Department of Child and Adolescent Psychiatry, Leiden University, P.O. Box 37, 2300 AA Leiden, The Netherlands. 4. Institute for Medical Technology Assessment & Institute of Health Policy & Management, P.O. Box 1738, 3000 DR, Erasmus University Rotterdam, The Netherlands.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of Multidimensional Family Therapy (MDFT) for adolescents with a cannabis use disorder, compared to Cognitive Behavioural Therapy (CBT). METHODS: A parallel-group randomized controlled trial was performed. 109 adolescents with a DSM-IV cannabis use disorder (CBT n=54; MDFT n=55) were included. Assessments were conducted at baseline, and 3, 6, 9 and 12 months post-baseline, and included measures on cannabis and other substance use, delinquency, health care utilization, and general health related quality of life. RESULTS: Excluding those with missing cost-data, 96 participants (MDFT n=49; CBT n=47) were included. From a health care perspective, the average annual direct medical costs in the CBT group were €2015 (95%C.I. 1397-2714), compared to €5446 (95%C.I. 4159-7092) in the MDFT group. The average quality-adjusted life years (QALY's) gained were 0.06 QALY higher for the MDFT group, which led to an incremental cost-effectiveness ratio (ICER) of 54,308 Euro/QALY or €43,405 per recovered patient. Taking the costs of delinquency into account, the costs increased to €21,330 (95%C.I. 12,389-32,894) for the CBT group and to €21,915 (95%C.I. 16,273-28,181) for the MDFT group, which lead to an ICER of 9266 Euro/QALY or a cost per recovered patient of €7491. CONCLUSIONS: This is the first comprehensive CEA of MDFT compared to CBT and it demonstrated that when costs of delinquency were included, the ICERS were modest. The results underline the importance of adopting a broader perspective regarding cost effectiveness analyses in mental health care.
RCT Entities:
OBJECTIVE: To evaluate the cost-effectiveness of Multidimensional Family Therapy (MDFT) for adolescents with a cannabis use disorder, compared to Cognitive Behavioural Therapy (CBT). METHODS: A parallel-group randomized controlled trial was performed. 109 adolescents with a DSM-IV cannabis use disorder (CBT n=54; MDFT n=55) were included. Assessments were conducted at baseline, and 3, 6, 9 and 12 months post-baseline, and included measures on cannabis and other substance use, delinquency, health care utilization, and general health related quality of life. RESULTS: Excluding those with missing cost-data, 96 participants (MDFT n=49; CBT n=47) were included. From a health care perspective, the average annual direct medical costs in the CBT group were €2015 (95%C.I. 1397-2714), compared to €5446 (95%C.I. 4159-7092) in the MDFT group. The average quality-adjusted life years (QALY's) gained were 0.06 QALY higher for the MDFT group, which led to an incremental cost-effectiveness ratio (ICER) of 54,308 Euro/QALY or €43,405 per recovered patient. Taking the costs of delinquency into account, the costs increased to €21,330 (95%C.I. 12,389-32,894) for the CBT group and to €21,915 (95%C.I. 16,273-28,181) for the MDFT group, which lead to an ICER of 9266 Euro/QALY or a cost per recovered patient of €7491. CONCLUSIONS: This is the first comprehensive CEA of MDFT compared to CBT and it demonstrated that when costs of delinquency were included, the ICERS were modest. The results underline the importance of adopting a broader perspective regarding cost effectiveness analyses in mental health care.
Authors: Vivian T Reckers-Droog; Maartje Goorden; Marcel G W Dijkgraaf; Hester V Van Eeren; Kathryn E McCollister; Leona Hakkaart-van Roijen Journal: J Ment Health Policy Econ Date: 2019-06-01
Authors: Matthew C Fadus; Lindsay M Squeglia; Emilio A Valadez; Rachel L Tomko; Brittany E Bryant; Kevin M Gray Journal: Curr Psychiatry Rep Date: 2019-09-14 Impact factor: 5.285
Authors: S Schawo; C Bouwmans; E van der Schee; V Hendriks; W Brouwer; L Hakkaart Journal: Health Qual Life Outcomes Date: 2017-09-19 Impact factor: 3.186
Authors: Jakob Mechler; Karin Lindqvist; Per Carlbring; Peter Lilliengren; Fredrik Falkenström; Gerhard Andersson; Naira Topooco; Robert Johansson; Nick Midgley; Julian Edbrooke-Childs; Hanne-Sofie J Dahl; Rolf Sandell; Agneta Thorén; Randi Ulberg; Katja Lindert Bergsten; Björn Philips Journal: Trials Date: 2020-06-29 Impact factor: 2.279
Authors: Thimo M van der Pol; Vincent Hendriks; Henk Rigter; Moran D Cohn; Theo A H Doreleijers; Lieke van Domburgh; Robert R J M Vermeiren Journal: Child Adolesc Psychiatry Ment Health Date: 2018-08-17 Impact factor: 3.033